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Abstract. 
Cancer-related hypercalcemia is a relative common complication from breast cancer with 
bone metastasis and may cause renal failure and coma in severe condition. The cornerstone of 
treatment is vigorous hydration, intravenous bisphosphonates, and loop diuretic agent only after 
corrected hypovolemia. Bisphosphonates is related deterioration of renal function and is con-
troversial when administered in cancer-related hypercalcemia complicated markedly renal dete-
rioration. The receptor activator of nuclear factor-kappa Bligand (RANK-L) is an essential sig-
nal to stimulate differentiation, activity and survival of osteoclast. Denosumab, a fully human 
antibody which neutrolizes RANK-L leading to the loss of osteoclasts from bone surface and 
inhibition of bone resorption. Here, we present a case report of breast cancer-related hyper-
calcemia complicated renal failure was successfully treated by denosumab. 
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中文摘要 
  癌症相關高血鈣在乳癌合併骨轉移患者是個比較常見的併發症，嚴重者可能導致腎
衰竭及意識昏迷。治療的黃金準則為充足水份補充、靜脈注射雙磷酸鹽藥物以及在確定
低血容已矯正恢復後可以給予亨利氏環利尿劑。雙磷酸鹽藥物因有使腎功能變差之可能
性，是否可用來治療癌症相關高血鈣併發嚴重腎功能損傷之患者，仍有爭議。細胞核因
子 Kappa B 受體活化因子之配體(RANK-L)是促使蝕骨細胞分化、具有活性以及存活的一
個必需訊息傳遞訊號。Denosumab 為一全人類成份的抗體，可以中和掉 RANK-L 而使骨
頭表面的蝕骨細胞喪失，進而抑制骨頭的再吸收。我們在此報告一個以 denosumab 治療
乳癌相關高血鈣併發腎衰竭成功的患者。 
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INTRODUCTION 
Hypercalemia has been reported to occur in up to 
5 to 30 percent of patients with cancer during the 
course of their disease [1,2]. The most common can-
cers-inducing hypercalcemia are lung and breast can-
cers and multiple myeloma [2]. Hypercalcemia leads 
to a variety of symptoms in patients, which can range 
from confusion and polyuria to coma and death. The 
cornerstone of treatment is vigorous hydration, intra-
venous bisphosphonates, and loop diuretic agent only 
after corrected hypovolemia. 
Bisphosphates, such as zolendronic acid and 
palmidronate, are effective therapeutic agents for hy-
percalcemia [3]. However, in hypercalcemia compli-
cated with marked acute renal insufficiency, especially 
when serum creatinine is above 4.5 mg/dl, the usage 
of bisphosphanate sould be delayed [4]. Vigorous hy-
dration, loop diuretics, and calcitonin may be applied 
to lower the level of serum calcium. If renal function 
improves, bisphsphanate should be prescribed and 
may be followed by definite anti-cancer therapy which 
can be used to control the calcium level. Denosumab 
is a fully human antibody which neutralizes the re-
ceptor activator of nuclear factor-kappa Bligand 
(RANK-L) leading to the loss of osteoclasts from 
bone surface and inhibition of bone resorption. The 
benefits of denosumab for prevention of skeletal-  
related event of cancer with bony metastasis have 
been confirmed by recent large clinical trials [5-7]. 
Denosumab may have a more potent effect of bone 
resorption inhibition than zoledronic acid by improved 
skeletal-related events and more adverse events of 
hypocalcemia in the treatment of advanced breast 
cancer, castration-resistant prostate cancer and other 
advanced cancer with bone metastases [5-7]. Here, we 
report a case of hypercalcemia induced by advanced 
breast cancer with bone metastases and complicated 
with marked renal injury, successfully treated by 
denosumab. 
 
CASE REPORT 
A 40 year-old women was admitted to our hospital 
because of a left breast lump with pain for one year. 
Physical examination revealed a huge left breast mass 
with ulceration and enlarged nodes in the left axillary 
and periclavicular area. The biopsy of left breast tu-
mor disclosed invasive ductal carcinoma with positive 
ER (80%), PR (80%) and negative HER-2/neu. CT 
scans of the chest and abdomen revealed a huge left 
breast mass with skin invasion, axillary and neck 
lymphoadenopathy, multiple liver and bony metasta-
ses involving the right femoral head, right acetabulum, 
both pubic bones, right iliac bone and vetebral bodies 
from T10 to L4. Advanced breast cancer with multiple 
metastases was diagnosed. Marked hypercalcemia and 
renal failure were noted. The albumin-corrected serum 
calcium level was 16.74 mg/dL. The serum BUN and 
creatinine levels were 63 and 3.57 mg/dL respectively 
with estimated glomerular filtration rate 15 ml/min/ 
1.73m2. The serum parathyroid hormone and vitamin 
D3 were showen to be within the normal range, and 
cancer-induced hypercalcemia (CIH) was considered. 
Aggressive intravenous hydration was given initially 
and serum calcium and renal function declined slightly. 
Due to the markedly deteriorated renal function, deno-
sumab with one single dose of 120 mg was adminis-
tered subcutaneously. The following sequential data 
showed that the serum calcium level decreased to 
normal accompanied by gradually recovered renal 
failure (Figure 1) and then chemotherapy was admin-
istered. The serum calcium level was still in the nor-
mal range 22 days after denosumab injection. 
 
DISCUSSION 
Cancer-induced hypercalcemia (CIH) developed in 
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Figure 1. Time course of total serum calcium and serum creatinine levels in response 
to vigorous hydration and a single dose of denosumab administered (normal 
range of serum total calcium: 8.4~10.6 mg/dL, creatinine: 0.5~1.2 mg/dL) 
 
 
5 to 30 percent of patients with cancer, and breast 
cancer is one of the most common cancers associated 
with CIH. The mechanisms of CIH include secreting 
parathyroid hormone related protein (PTHrP) in 80% 
of patients, focal osteolytic bone destruction in 20% 
and other calciotropic hormones (<1%), including 
vitamin D3 and ectopic PTH. Osteoclastic bone re-
sorption can be induced by the any of the three mech-
anisms and calcium releases from the bone matrix 
[1,2]. Standard treatment of CIH comprises vigorous 
hydration, intravenous bisphosphonates (BPs), and 
loop diuretics only after corrected hypovolemia. 
However, bisphosphonates are excreted intact primar-
ily via the kidney and have a risk to deteriorate renal 
function. Higher serum concentration as well as great-
er adverse events of deterioration of renal function are 
noted when administered in patients with initially im-
paired renal function [3]. In patients of malignancy 
with bone metastasis, dose adjustment for zoledronic 
acid is needed if renal insufficiency is mild to moder-
ate ( creatinine clearance between 30 to 60 ml/min per 
1.73 m2) but administration of bisphosphates is dis-
couraged if creatinine clearance is below 30 ml/min 
per 1.73 m2 [2,5-7]. In patients with hypercalcemia, a 
malignancy with severe renal impairment should be 
considered only after evaluating the benefits and risk 
of treatment. In the clinical trial, patients with serum 
creatinine above 4.5 mg/dL were excluded [4]. In the 
study of Major et al, a pooled analysis of two ran-
domized trials comparing zoledronic acid and pami-
dronate in the treatment of hypercalcemia due to a 
malignancy included patients whose serum creatinine 
levels were less than 4.5 md/dL. The result showed 
that the complete remission rates of hypercalcemia in 
the zoledronic acid group and the pamidronate group 
were 86.7% and 69.7% (p =0.015), respectively. 
However, the rates of grade 3 or 4 renal toxicity were 
still high (2.3~5.2% in the zoledronic acid group and 
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4.0% in the pamidronate group) [4]. 
The receptor activator of nuclear factor-kappa 
Bligand (RANK-L) is an essential signal to stimulate 
differentiation, activity and survival of osteoclast. 
Denosumab, a fully human antibody, neutralizes 
RANK-L leading to the loss of osteoclasts from bone 
surface and inhition of bone resorption [8]. In the 
phase III trial of bone metastases in patients with ad-
vanced breast cancer, 1901 patients were randomly 
assigned to receive denosumab or zoledronic acid for 
prevention of skeletal-related events. The results 
demonstrated a more prolonged median time to the 
first on-study skeletal-related event (26.4 months in 
the zoledronic acid group, but the time has not yet 
been reached in the denosumab group, the hazard ratio 
being 0.82, p = 0.01). A greater reduction in bone 
turnover marker in the denosumab group (p< 0.0001) 
was found also. In the issue of adverse effects, there 
are more hypocalemia events in the denosumab group 
(5.5% vs. 3.4%) and less renal failure events in the 
denosumab group (0.2% vs. 2.5%) [7]. These results 
showed that denosumab was more effective and had 
less renal toxicity than bisphosphonates. Denosumab 
is a monoclonal antibody and metabolized by pepti-
dases and cleared by the reticuloendothelial system, 
and probably dose not exert nephrotoxic effects [9]. 
The American Society of Clinical Oncology executive 
summary of the clinical practice guideline on the role 
of bone-modifying agents in metastatic breast cancer 
published in 2011 suggested 1) dose adjustment of 
bisphosphates when baseline serum creatinine clear-
ance is ≥ 30 and < 60 mL/min, 2) patients with creati-
nine clearance < 30 mL/min or on dialysis may be 
treated with denosumab, with close monitoring for 
hypocalcemia is recommended [10]. However, despite 
the reduced dose of zoledronic acid in patients with 
cancer whose creatinine clearance was less than 60 
mL/min per 1.73 m2, deterioration of renal function 
(all grades) was observed in 20 to 21.6% of patients 
treated with bisphosphonates. Compared with deno-
sumab, it occurred only in 5.9 to 11.3% of those 
treated with denosumab [5,7]. 
Denosumab for treatment of cancer induced hy-
percalemia is still not approved by FDA due to the 
lack of large and randomized studies. One phase 2 
clinical trials which used denosumab for bisphos-
phate-refractory hypercalcemia induced by a malig-
nancy was published in June, 2014. There were 33 
patients with bisphosphate-refractory hypercalcemia 
due to the malignancy who received subcutaneous 
denosumab 120 mg on days 1, 8, 15 and 29, and every 
4 weeks thereafter. The response rate after 10 days 
was 64% (calculated serum calcium ≤ 11.5 mg/dL and 
the complete response rate during the study was also 
64% (calculated calcium ≤ 10.8 mg/dL). Besides, no 
renal toxicity was observedin patients with an im-
paired renal function response to denosumab therapy 
[11]. Another study of case series presented 7 patients 
of cancer-related hypercalcemia who received deno-
sumab treatment. All but one have received bisphos-
phate therapy. Two patients received a single dose of 
denosumab 60 mg and the other five received 120 mg. 
Five patients achieved normalized calcium levels 
within 17 h after denosumab administration [12]. 
In Taiwan, the costs are similar between 120 mg of 
denosumab and 4 mg of zoledronic acid. The payment 
is NT 12,703 dollars for denosumab and NT 12,384 
for zoledronic acid by Taiwan National Health Insur-
ance. However, denosumab is deemed to be more ef-
fective for reducing skeletal-related events.  
 Denosumab is an effective therapy for cancer- 
induced hypercalcemia and should be considered a 
safe treatment for patient complicated with severe 
renal insufficiency. In our case and previous case se-
ries studies, a single dose of denosumab (120 mg) 
seems to be effective initially for hypercalcemia of 
malignancy and frequently repeated dose can be re-
served for refractory hypercalcemia. 
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